DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma Inc. (the 'Company' or 'Aytu') (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024.

丹佛，CO/ACCESSWIRE/2024年5月8日/Aytu BioPharma Inc.（以下简称“公司”或“Aytu”）（纳斯达克：Aytu），一家专注于新型治疗药物商业化的制药公司，将在2024年5月15日周三市场收盘后，报告其2024财年第三季度截至2024年3月31日的财务和运营结果。

The Company has scheduled a conference call and webcast that same day, Wednesday, May 15, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session..

该公司计划在2024年5月15日（星期三）东部时间下午4:30召开电话会议和网络广播，审查结果，然后进行问答。。

Conference Call Details

电话会议详细信息

Date and Time: Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time

日期和时间：2024年5月15日星期三，东部时间下午4:30

Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for U.S. callers or +1 (973) 528-0011 for international callers and using the participant access code 300411.

来电信息：感兴趣的各方可以通过拨打（888）506-0062（美国来电者）或+1（973）528-0011（国际来电者）并使用参与者接入代码300411来访问会议电话。

Webcast Information: The webcast will be accessible live and archived at https://www.webcaster4.com/Webcast/Page/2142/50379, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.

网络广播信息：网络广播将在https://www.webcaster4.com/Webcast/Page/2142/50379，并可在公司网站的投资者部分访问https://investors.aytubio.com/在“活动与演示”下。

Replay: A teleconference replay of the call will be available until May 29, 2024 at (877) 481-4010 for U.S. callers or +1 (919) 882-2331 for international callers and using replay access code 50379.

重播：电话会议重播将在2024年5月29日之前提供，美国呼叫方为（877）481-4010，国际呼叫方为+1（919）882-2331，重播接入码为50379。

About Aytu BioPharma, Inc.

关于艾图生物制药股份有限公司。

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency.

Aytu是一家专注于新型疗法商业化的制药公司。该公司的处方产品包括用于治疗注意力缺陷多动障碍（ADHD）的Adzenys XR-ODT®（安非他明）缓释口腔崩解片（请参阅完整的处方信息，包括盒装警告）和Cotempla XR-ODT®（哌醋甲酯）缓释口腔崩解片（请参阅完整的处方信息，包括盒装警告），用于治疗多种过敏性疾病的缓释抗组胺混悬剂Karbinal®ER（马来酸卡宾沙明），以及Poly-Vi-Flor®和Tri-Vi-Flor®，这两种互补的含氟处方维生素产品系列可用于各种配方中，用于氟化物缺乏的婴儿和儿童。

To learn more, please visit aytubio.com..

要了解更多信息，请访问aytubio.com。。

Contacts for Investors:

投资者联系人：

Mark Oki, Chief Financial Officer

首席财务官Mark Oki

Aytu BioPharma, Inc.

艾图生物制药股份有限公司。

moki@aytubio.com

moki@aytubio.com

Robert Blum or Roger Weiss

Robert Blum或Roger Weiss

Lytham Partners

Lytham Partners

aytu@lythampartners.com

aytu@lythampartners.com

SOURCE: Aytu BioPharma, Inc.

照片：艾图生物制药股份有限公司。

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿